First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient and response to alectinib with a 4-year follow-up

The prevalence of Anaplastic Lymphoma Kinase gene (ALK) fusion is about 5% among patients with lung adenocarcinoma, underscoring the importance of pinpointing distinct fusion variants for optimizing treatment approaches. This is the first reported case of a 74-year-old female with stage IV lung aden...

Full description

Bibliographic Details

Published in:	Frontiers in Genetics
Main Authors:	Zheng Mo, Cunliang Cai, Jingjing Yao, Jingquan Zhao, Mingqiang Zhang, Hao Liu, Xiangdong Mu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Subjects:	anaplastic lymphoma kinase (ALK fusion) case report kinesin family member 13A (KIF13A) lung adenocarcinoma alectinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2023.1289346/full